ストックスクリーナーアプリを入手
204.03
0.47%
-0.96
アフターアワーズ：
204.03
前日終値:
$204.99
開ける：
$207.3
24時間の取引高:
1.57M
Relative Volume:
0.37
時価総額：
$316.42B
収益：
$58.80B
当期純損益:
$10.24B
株価収益率:
62.23
EPS:
3.2788
ネットキャッシュフロー:
$8.98B
1週間 パフォーマンス:
+0.27%
1か月 パフォーマンス:
+4.64%
6か月 パフォーマンス:
+141.37%
1年 パフォーマンス:
+214.52%
1日の値動き範囲:
$203.82
$207.30
1週間の範囲:
$196.95
$207.30
52週間の値動き範囲:
$64.44
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
204.03 | 316.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
LLY
Lilly Eli Co
|
939.47 | 839.28B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
238.46 | 574.36B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
207.94 | 367.80B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
121.42 | 299.89B | 64.93B | 18.26B | 12.36B | 7.2751 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-27 | 開始されました | Citigroup | Buy |
| 2025-10-27 | 再開されました | Jefferies | Buy |
| 2025-10-16 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 開始されました | Exane BNP Paribas | Outperform |
| 2025-02-13 | アップグレード | UBS | Neutral → Buy |
| 2025-02-12 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-20 | アップグレード | UBS | Sell → Neutral |
| 2024-11-06 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-09-13 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-16 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-02-08 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Sell |
| 2024-01-03 | ダウングレード | Jefferies | Buy → Hold |
| 2023-12-18 | 開始されました | HSBC Securities | Buy |
| 2023-09-25 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-07-12 | アップグレード | UBS | Neutral → Buy |
| 2023-07-05 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-04-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2022-09-15 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | アップグレード | Argus | Hold → Buy |
| 2022-06-14 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-11 | アップグレード | DZ Bank | Sell → Hold |
| 2021-12-07 | ダウングレード | Jefferies | Buy → Hold |
| 2021-08-12 | 再開されました | JP Morgan | Overweight |
| 2021-04-12 | ダウングレード | Argus | Buy → Hold |
| 2021-03-16 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | アップグレード | UBS | Neutral → Buy |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-12-07 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | アップグレード | UBS | Sell → Neutral |
| 2020-11-11 | アップグレード | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2019-11-22 | 開始されました | SVB Leerink | Outperform |
| 2019-10-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-02 | ダウングレード | UBS | Neutral → Sell |
| 2019-02-05 | 開始されました | Exane BNP Paribas | Outperform |
| 2019-01-25 | アップグレード | Shore Capital | Hold → Buy |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-08-16 | ダウングレード | Jefferies | Buy → Hold |
| 2018-03-19 | アップグレード | Jefferies | Hold → Buy |
| 2018-02-06 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-05 | 繰り返されました | Bernstein | Outperform |
| 2018-01-18 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2017-12-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-10-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | アップグレード | Bernstein | Mkt Perform → Outperform |
すべてを表示
Astrazeneca Plc (AZN) 最新ニュース
Parnassus Value Equity Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage - Yahoo Finance
Is AstraZeneca Still in Focus After Strong Market Momentum? - Kalkine Media
AstraZeneca Wins Strong Shareholder Backing at 2026 AGM - The Globe and Mail
AstraZeneca faces China headwinds and key drug launches as two banks back 20% upside - Yahoo! Finance Canada
AstraZeneca India Expands Cancer Drug Use, Stock Gains on Approval - Whalesbook
ASTRAZENECA : UBS gives a Buy rating - marketscreener.com
7MM Systemic Lupus Erythematosus and Lupus Nephritis Drug Market Analysis & Forecast 2024-2034: Future SLE and LN Players Competition, High Unmet Need for Steroid-sparing Treatments - GlobeNewswire Inc.
ASTRAZENECA : Jefferies reaffirms its Buy rating - marketscreener.com
PDL1 Antibody Reagent Market is Going to Boom: AstraZeneca • Pfizer • Novartis • Abcam - openPR.com
AstraZeneca shareholders approve all resolutions at annual general meeting - Investing.com
AstraZeneca shareholders approve all resolutions at annual general meeting By Investing.com - Investing.com UK
AstraZeneca (AZN) shareholders back all AGM resolutions and buyback - Stock Titan
AstraZeneca Triumphs at AGM: All Resolutions Passed - Devdiscourse
AstraZeneca announces all AGM resolutions including Special Resolutions 10-13 passed - marketscreener.com
AstraZeneca, Sun Dismiss Patent Suits Over Three Diabetes Drugs - Bloomberg Law News
Ideaya Biosciences announces clinical collaboration with AstraZeneca for lung cancer study - Investing.com India
$1.05 Bn Biopharmaceutical CXO MarketsGlobal Forecast Report 2026-2032: How Leading Pharmas Such as Pfizer, Roche, Novartis, Sanofi, and AstraZeneca Navigate the Evolving Dynamics - Yahoo Finance
IDEAYA Biosciences (NASDAQ: IDYA) teams with AstraZeneca on IDE849-Imfinzi SCLC trial - Stock Titan
Cowen Maintains Buy on AstraZeneca PLC (AZN) March 2026 - Meyka
AstraZeneca Wants 25 Opt-Ins Axed From Pay Bias Suit - Law360
AstraZeneca (NYSE: AZN) delists 0.700% Notes due 2026 from NYSE - Stock Titan
AstraZeneca Extends Fasenra’s Runway With New Long-Term Safety Study - TipRanks
AstraZeneca : Sustainability Data Reporting Criteria 2025 - marketscreener.com
AstraZeneca : Assurance Report for Sustainability Data Annex 2025 - marketscreener.com
AstraZeneca : Sustainability Data Annex 2025 - marketscreener.com
AstraZeneca Partners with Telangana Government to Introduce AI-Based Lung Cancer Screening - The Indian Practitioner
£20,000 invested in AstraZeneca shares 5 years ago is now worth… - Fool UK
Sit Dividend Growth Fund's AstraZeneca PLC(AZN) Holding History - GuruFocus
Top Research Reports for AstraZeneca, HSBC & Walt Disney - Yahoo Finance
Morgan Stanley raises AstraZeneca stock price target on pipeline progress By Investing.com - Investing.com UK
AstraZeneca, Telangana govt to roll out AI-powered lung cancer screening in public hospitals - The Times of India
What’s going on with the AstraZeneca share price now? - Fool UK
AstraZeneca's liver cancer breakthrough puts Imfinzi on course to become a super-blockbuster drug - Proactive Investors
AstraZeneca PLC (AZN) stock price, news, quote and history - Yahoo Finance Singapore
ASTRAZENECA : JP Morgan reiterates its Buy rating - marketscreener.com
AstraZeneca PLC (AZN) Stock Price, News, Quote & History - Yahoo! Finance Canada
AstraZeneca stock gains 1.77% as strong oncology-driven revenue and earnings growth boosts sentiment - Traders Union
Perpetual Ltd Has $515,000 Stock Holdings in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca Plc $AZN Stock Holdings Lowered by Cidel Asset Management Inc. - MarketBeat
AstraZeneca reports positive EMERALD-3 results for HCC - Clinical Trials Arena
AstraZeneca PLC (AZN.L) Stock Price, News, Quote & History - Yahoo! Finance Canada
AstraZeneca PLC (AZN.L) stock price, news, quote and history - Yahoo Finance UK
AstraZeneca: The Bigger Picture Remains Solid Growth Amidst Improving Margins And Returns - Seeking Alpha
Allspring Large Cap Growth Fund's AstraZeneca PLC(AZN) Holding History - GuruFocus
Aberdeen Group plc Grows Stake in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca (NYSE:AZN) Cut to Hold at Wall Street Zen - MarketBeat
FTSE AstraZeneca PLC Index (SSAZNS.FGI) Forum & Discussion - Yahoo! Finance Canada
SA T. Rowe Price VCP Balanced Portfolio's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca stock gains 1.77% as bullish technicals and positive trial results fuel buying - Traders Union
AstraZeneca PLC stock: Positive liver cancer trial results spark investor interest - AD HOC NEWS
AZN Stock Quote Price and Forecast - CNN
Astrazeneca Plc (AZN) 財務データ
収益
当期純利益
現金流量
EPS
1.03%
大文字化:
|
ボリューム (24 時間):